Possibly. Yixin Medical Group is the world's leading innovative cardiovascular medical device platform company. Its products mainly include interventional heart valve treatment products, interventional coronary drug balloon products, and interventional heart failure treatment products. They are all products with global intellectual property rights and world-leading technology. The interventional mitral valve replacement product owned by Yixin Medical Group is the only product in the world that can match the transapical and transfemoral venous delivery paths with the same valve. The transapical delivery device and the transfemoral venous delivery device have the same smallest delivery capacity in the world. It is also the only fully ultrasound-guided patient operation at present.
The skin-to-skin time of transapical mitral valve interventional replacement surgery is only 10 minutes. The doctor’s learning curve is short, and the patient’s long-term follow-up quality of life is good. This product will greatly benefit Chinese patients when it enters the market in the future. Its coronary drug balloon products also have the world's leading technology. This technology is the fourth generation drug coating technology. Its first, second and third generation technologies have accumulated nearly 600,000 clinical data in the global market. Its safety and The effectiveness has been effectively verified. Yixin Medical Group stated that the investment in Yixin by top investment institutions in the industry shows the market's high recognition and support for Yixin Medical. Yixin Medical Group will continue to develop the world's leading technological innovation and industrialization/commercialization of cardiovascular interventional medical devices, and build the company into a leading cardiovascular platform company in China and even the world. The company will use independent innovation as its primary driving force, integrate and deploy global superior technologies, and provide doctors and patients with world-class overall solutions for interventional treatment of heart disease.
Mr. Chen Zhixing, executive director of Dazheng Capital, said: "The patient population with mitral regurgitation is huge, but current treatment methods are limited, and safe and effective interventional technology is urgently needed clinically. The technical concept and process level of cusp replacement products are at the forefront of the world, and the potential market value is huge. We will fully support the establishment of Cardiovascular as a leading cardiovascular and cerebrovascular medical device platform company in China, and promote the launch of more innovative medical products in the Chinese market. , benefiting a large number of Chinese patients.” Ms. Liang Ying, head of CICC Qide Fund, said: “China’s cardiovascular market is huge and continues to grow. There is an urgent need for mitral valve treatment, and the market is still emerging and has broad prospects. p>
Because the technical threshold is extremely high, there is no interventional mitral valve replacement product on the market in China. The company has the world's top Chinese and foreign scientists, engineers and cardiovascular interventional doctors, giving the company strong original research and development capabilities and capabilities. Rich clinical resources. We are determined to grow with the company and build the world's leading enterprise in the cardiovascular interventional field. ”